Phloroglucinol
A03A - Drugs for functional bowel disorders
ATC A03AX12
Small molecule
Natural product
JFDA label: Phlorofon
Mechanism of Action
Blocker of Voltage-gated calcium channel — Voltage-gated calcium channel blocker
| Target | Action | Gene / class |
|---|
| Voltage-gated calcium channel efficacy |
BLOCKER |
|
Indications
Approved
- Digestive System Diseases — gastrointestinal disease
Chemistry & Properties
| Formula | C6H6O3 |
|---|
| Molecular weight | 126.11 g/mol |
|---|
| IUPAC name | benzene-1,3,5-triol |
|---|
| CAS | 108-73-6 |
|---|
| PubChem CID | 359 |
|---|
| InChIKey | QCDYQQDYXPDABM-UHFFFAOYSA-N |
|---|
| logP | 0.8 (XLogP 0.2) |
|---|
| Polar surface area | 60.69 Ų |
|---|
| H-bond acceptors / donors | 3 / 3 |
|---|
| Drug-likeness (QED) | 0.48 |
|---|
| Lipinski violations | 0 |
|---|
SMILES
Oc1cc(O)cc(O)c1Biology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|
| Half-life | 1.332 h |
|---|
| Volume of distribution | 0.905 L/kg |
|---|
| Protein binding | 52.8% |
|---|
| BBB penetrant | No |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|
| CYP1A2 | Inhibitor |
— |
| CYP1A2 | Substrate |
— |
| CYP2B6 | Inhibitor |
— |
| CYP2C19 | Inhibitor |
— |
| CYP2C8 | Inhibitor |
— |
| CYP2C9 | Inhibitor |
— |
| CYP2C9 | Substrate |
— |
| CYP2D6 | Inhibitor |
— |
| CYP2D6 | Substrate |
— |
| CYP3A4 | Inhibitor |
— |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (1)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|
| Phlorofon
|
Ampoule 40 mg/4 ml, 0.04 mg/4 ml |
6 amp |
THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY/JORDAN |
3.190 |